PRESS RELEASE Read more Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023 PATIENT STORIES For someone with Tyrosinemia Type 1 I understand the struggle you are going through every single day – remembering to take your medicine, your formula, sticking to your diet – and it’s not the most fun thing to do. But it’s also not that hard with NITYR JAMIE Jamie was Diagnosed with Tyrosinemia Type 1 (HT-1) PATIENT STORIES Five-year-old Ethan has Tyrosinemia Type 1 (HT-1). Like any family that has a child with this ultra rare condition, the family have found Ethan’s diet and medication regime very demanding. ETHAN Ethan was Diagnosed with Tyrosinemia Type 1 (HT-1) PATIENT STORIES When Alina’s parents learned she had Tyrosinemia Type 1 (HT-1), they were understandably concerned. But, with NITYR, they have a safe, proven medicine that allows Alina to live life to the fullest. ALINA Alina was Diagnosed with Tyrosinemia Type 1 (HT-1) PATIENT STORIES Thanks to NITYR, Mazin has the chance to live his life like any other kid, and his parents are very thankful to be able to see him grow up in good health and enjoy his unique personality.
MAZIN Mazin was Diagnosed with Tyrosinemia Type 1 (HT-1)

WHAT WE DO

Cycle Pharmaceuticals is a global, privately-owned and patient-dedicated biotechnology company headquartered in Cambridge in the UK. Our mission is to utilise the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. In addition, we provide individualised patient support services to meet patient needs swiftly and efficiently.

ABOUT US

PATIENTS